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The fountain of youth: remove old 
cells and you will be young again
Baker et al., Nature 2011; 479: 232–236; doi:10.1038/nature10600
With ageing, senescent cells accumulate in various tissues and 
organs and have been hypothesized to disrupt tissue structure 
and function because of the components they secrete. However, 
whether senescent cells are causally implicated in age-related dys-
function and whether their removal is beneficial have remained 
unknown. To address this question, Baker et al. present a novel 
transgenic mouse model that allows for the inducible removal of 
p16Ink4a-positive senescent cells. By breeding these mice into a 
genetic progeroid, rapidly ageing mouse background, they showed 
that both lifelong and late-life clearance of the p16Ink4a-expressing 
senescent cells selectively delayed age-related pathologies in tissues 
that accumulate these cells, such as adipose tissue, skeletal mus-
cle, and eye (Figure). Furthermore, late-life clearance attenuated 
progression of already established age-related disorders. The data 
also indicate that acquisition of the senescence-associated secre-
tory phenotype, which enables cells to secrete a variety of growth 
factors, cytokines, and proteases, contributes to age-related tissue 
dysfunction. These proof-of-principle experiments indicate that 
cellular senescence is causally implicated in generating age-related 
phenotypes and that removal of senescent cells can prevent or 
delay tissue dysfunction and extend healthspan.
The generation of a mouse strain allowing elimination of 
senescent cells with high p16Ink4a expression should now allow 
examination of the question of whether senescence contributes 
to the decline of renal function with age and potentially even to 
the progression of renal disease in general.
Detlef Schlöndorff
Elevated plasma FGF23 and left 
ventricular hypertrophy in chronic 
kidney disease
Faul et al., J Clin Invest 2011; 121: 4393–4408; doi:10.1172/JCI46122
Patients with chronic kidney disease (CKD) not only face the 
possibility of end-stage renal failure but also have increased risk 
of premature death; cardiovascular disease is the leading cause. 
Left ventricular hypertrophy (LVH) is an important mechanism 
of cardiovascular disease, as it contributes to diastolic dysfunction, 
congestive heart failure, arrhythmia, and sudden death. LVH affects 
50–70% of patients with early CKD and up to 90% by the time they 
reach dialysis. It is likely that hypertension is a major contributor to 
these very high rates of LVH, but other CKD-specific mechanisms 
might also be involved. Clinical observations have long suggested 
a specific phenotype of cardiac hypertrophy in CKD (that is, ‘ure-
mic cardiomyopathy’), and the remarkable regression of LVH after 
kidney transplantation suggests the presence of hypertension-inde-
pendent mechanisms that remain undefined. The family of fibro-
blast growth factors (FGFs) consists of 23 proteins that regulate 
cell proliferation, migration, differentiation, and survival; FGF2 is 
the best-studied and prototypical factor. FGF2 can cause cardiac 
hypertrophy, but FGF2 and other canonical FGFs appear to exert 
their effects in a paracrine or autocrine manner as they bind hep-
aran sulfate in the extracellular matrix. In contrast, the particular 
structure of FGF23 enables it to avoid capture by the extracellular 
matrix and to function as an endocrine hormone that regulates 
phosphorus homeostasis through binding to FGF receptors and 
klotho, its co-receptor in the kidney and parathyroid glands. The 
best-understood actions of FGF23 are to augment phosphaturia by 
downregulating expression of sodium-phosphate cotransporters in 
the renal proximal tubule and to decrease circulating concentrations 
of 1,25-dihydroxyvitamin D. As the renal capacity for phosphorus 
BubR1H/H;INK-ATTAC mice treated with AP20187 from weaning 
age on show delayed onset of p16Ink4a-mediated age-related 
phenotypes. Representative images of 9-month-old mice.
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Pharmacological inhibition of FGF receptors attenuates LVH in an 
animal model of CKD. (a) FGF receptor blocker PD173074 attenuated 
the increases in left ventricular mass and cardiac weight/body weight 
that developed in 5/6 nephrectomized rats treated with vehicle (*P < 
0.05 compared with sham; **P < 0.05 compared with 5/6 nephrectomy 
treated with vehicle). White bars, sham; red bars, 5/6 nephrectomy; 
blue bars, 5/6 nephrectomy plus PD173074. (b) Representative gross 
pathology sections (hematoxylin and eosin stain; scale bars, 400 
mm) from the left ventricular mid-chamber (MC) at day 14 after 5/6 
nephrectomy. WGA, wheat germ agglutinin.
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excretion declines in CKD, plasma FGF23 levels progressively 
increase, and they can reach 1000-fold above normal in advanced 
renal failure. The elevated plasma FGF23 levels help patients with 
CKD maintain normal serum phosphate levels. However, studies 
of CKD and non-CKD patients demonstrated a dose-dependent 
association between elevated FGF23 levels and greater risks of 
major cardiovascular events and mortality, and elevated FGF23 
was independently associated with greater left ventricular mass 
and greater prevalence of LVH. Faul et al. recently examined the 
potential role of FGF23 in the pathogenesis of LVH and found that 
FGF23 caused pathological hypertrophy of isolated rat cardiomyo-
cytes via FGF receptor-dependent activation of the calcineurin–
NFAT signaling pathway, but this effect was independent of klotho, 
the co-receptor for FGF23 in the kidney and parathyroid glands. 
Moreover, intramyocardial or intravenous injection of FGF23 in 
wild-type mice resulted in LVH, and klotho-deficient mice demon-
strated elevated FGF23 levels and LVH. Finally, in mice with a 5/6 
nephrectomy, treatment with an FGF receptor blocker attenuated 
LVH (Figure), although no change in blood pressure was observed.
Although exclusion of the contribution of the level of blood pres-
sure to cardiovascular diseases in small rodents is extremely dif-
ficult, this study strongly suggests a causal role for FGF23 in the 
pathogenesis of LVH that is independent of klotho. Thus, the chron-
ically elevated FGF23 plasma levels in patients with CKD might 
directly contribute to their high rates of LVH and mortality. The 
therapeutic implications of these findings might be considerable.
Juan Oliver
Indoxyl sulfate, a representative 
uremic toxin, suppresses 
erythropoietin production in  
a HIF-dependent manner
Chiang et al., Lab Invest 2011; 91: 1564–1571; doi:10.1038/labinvest.2011.114
The majority of patients with progressive renal failure develop a 
certain degree of anemia through insufficient erythropoietin (EPO) 
production by peritubular fibroblasts. Recent studies have shown 
an increase in EPO production by pharmacological activation of 
hypoxia-inducible transcription factors (HIFs) in dialysis patients, 
suggesting that desensitization of the oxygen-sensing mechanism 
is responsible for the development of renal anemia. Chiang and 
colleagues investigated the possible links of uremic toxins to the 
desensitization of the oxygen-sensing mechanism in EPO-pro-
ducing cells. They investigated the effect of indoxyl sulfate (IS), 
an organic compound retained in the bodies of patients suffering 
from chronic renal failure, on EPO expression in HepG2 cells in 
vitro, and of transient IS accumulation on renal EPO expression 
in rats in vivo. HepG2 cells were stimulated with cobalt chloride 
(CoCl2) or hypoxia under varying concentrations of IS. Transcrip-
tional activity of HIF was checked by hypoxia-responsive element 
(HRE)-luciferase reporter assay. The researchers further evalu-
ated the impact of IS in vivo by administering indole, a metabolic 
precursor of IS, to rats, then subjecting them to CoCl2 stimulation 
and measuring renal EPO mRNA and plasma EPO levels. Although 
IS induced cellular toxicity at relatively high concentrations (≥2.5 
mM), EPO mRNA expression was significantly suppressed by IS at 
concentrations below cytotoxic ranges. In HepG2 cells, IS treatment 
decreased nuclear accumulation of HIF-a proteins and suppressed 
HRE-luciferase activity following hypoxia. Furthermore, adminis-
tration of indole to rats suppressed renal EPO mRNA expression 
and plasma EPO levels, corroborating in vitro findings.
The results of the present study provide a possible connection 
between a uremic toxin and the desensitization of the oxygen-
sensing mechanism in EPO-producing cells, which may partly 
explain inadequate EPO production in hypoxic kidneys of CKD 
patients. Further studies antagonizing the suppressing effects of IS 
may facilitate the availability of HIFs and represent a novel thera-
peutic approach in renal anemia.
Marc De Broe
Pyridoxamine dihydrochloride 
 in type 2 diabetic nephropathy
Lewis et al., J Am Soc Nephrol advance online publication, 27 October 2011, 
doi:10.1681/ASN.2011030272
Drug development generally proceeds in four phases. Phase 1 
studies are the first to expose humans to the agent and confirm the 
absence of any safety issues. Phase 2 studies focus on characterizing 
a potential dose–response relationship with respect to efficacy, lead-
ing to the ultimate phase 3 studies to truly define efficacy. A phase 2 
trial by Lewis et al. examines the effect of two doses of pyridoxamine 
dihydrochloride as compared with placebo on the progression of 
kidney disease among people with type 2 diabetic nephropathy. Par-
ticipants had to have proteinuria in excess of 1.2 g/d on maximum 
doses of angiotensin receptor blockers, and 317 were randomized 
to pyridoxamine dihydrochloride at a dose of 150 or 300 mg twice 
daily or placebo. Overall, participants had significant kidney disease 
at entry with a mean serum creatinine level of 2.20 mg/dl and a 
mean urine protein–creatinine ratio of 2.973 (g/24 h). In the cohorts 
overall, there was no difference in change in creatinine at 52 weeks. 
Creatinine rose by 0.36, 0.42, and 0.36 mg/dl in the placebo, 150-mg, 
and 300-mg groups, respectively. In prespecified subgroup analyses, 
however, the effect of treatment differed on the basis of baseline 
creatinine. Among participants with a serum creatinine level less 
than 2.0 mg/dl at baseline, changes in creatinine at 52 weeks were 
0.28, 0.13, and 0.14 mg/dl in the three groups, respectively, favor-
ing active treatment. Similar conclusions were derived by analysis 
based on tertile of creatinine, with the lowest tertile demonstrating 
a potential treatment effect. Proteinuria, however, was unaffected by 
treatment, irrespective of baseline kidney function.
Therein lies the need for careful interpretation of early-phase 
trials. In the discussion, the authors balance the limitations of 
subgroup analyses with the similarities between these results and 
those of the animal studies demonstrating treatment benefit. In light 
of the favorable safety profile seen, they conclude that a properly 
powered study in this sub-population (perhaps a phase 2b) is the 
appropriate next step. 
Lynda Szczech
